Skip to main content

Self Amplifying RNA IL-12 Delivery Enhanced Tumor Control In Mice: Silva-Pillipich et al. (Cell: 2022)

Alphavirus vectors utilizing self-amplifying RNA (saRNA) can generate transient yet potent transgene expression while eliciting innate immune responses, making them a promising tool for antitumor therapy. Typically, these vectors are delivered as viral particles, but they can also be administered as RNA. 

To explore this, Silva-Pillipich et al. (Cell: 2022) investigated the in vivo electroporation of Semliki Forest virus (SFV) saRNA for localized treatment of subcutaneous MC38 colorectal tumors in mice. The researchers first optimized the saRNA electroporation conditions within the tumors using an SFV vector carrying the luciferase gene. Subsequently, they assessed the therapeutic potential of this approach using SFV saRNA encoding interleukin-12 (SFV-IL-12), a potent anti-tumor cytokine.

The delivery of SFV-IL-12 saRNA through electroporation significantly enhanced tumor control and improved overall survival compared to mice treated solely with electroporation or SFV-IL-12 saRNA alone. Furthermore, the effectiveness of SFV-IL-12 saRNA electroporation was further enhanced when combined with systemic PD-1 blockade. This therapeutic strategy was validated in a hepatocellular carcinoma tumor model, underscoring its potential as a valuable approach for cancer immunotherapy. Importantly, this method could be readily translated to clinical practice, particularly for tumors accessible via percutaneous means.



Interleukin-12 (IL-12) stands out as one of the most potent anti-tumoral cytokines due to its ability to stimulate T cells, natural killer (NK) cells, and NK T cells, and exert an antiangiogenic effect. However, systemic expression of IL-12 can lead to toxicity, primarily because of the induction of high levels of interferon (IFN)-γ. To address this challenge, strategies have been developed to enable localized expression of IL-12 within tumors, often employing viral vectors encoding this cytokine. These approaches have demonstrated impressive anti-tumor efficacy while minimizing toxicity. Nonetheless, the use of replicative viruses in therapeutic strategies carries inherent risks, and regulatory constraints can hinder their translation into clinical practice.

In light of these challenges, non-viral vectors, particularly RNA vectors, have garnered considerable interest. RNA-based therapies have shown promising expression capabilities and safety profiles, extending beyond vaccines to various therapeutic strategies. The main hurdle for these technologies lies in formulating them to reach target cells at the required therapeutic levels.

This study explores the use of an innovative approach based on in vivo electroporation to introduce self-amplifying RNA (saRNA) derived from Semliki Forest virus (SFV) into tumor cells, encoding the IL-12 transgene. The SFV vector consists of a single positive-strand RNA containing a viral replicase capable of self-amplifying the viral RNA within host cells. Importantly, this vector lacks the genes encoding viral structural proteins, which are replaced by the transgene of interest. The mRNA coding for the desired protein is abundantly amplified from a viral subgenomic promoter (sgPr) present in the negative-strand RNA produced during the replication process. Consequently, this system achieves very high and transient expression of the transgene, while also inducing interferon-I (IFN-I) responses and apoptosis in the transduced cells. In this research, the focus was on optimizing the intratumoral electroporation conditions for SFV saRNA. The results highlighted effective anti-tumor immune responses in murine models of colon and liver cancer when employing the SFV-IL-12 vector delivered through this innovative approach.


Reference 

https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(22)00189-5


Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

SOP on Investigator Delegation of Authority

Title: Investigator Delegation of Authority Introduction and Purpose: This Standard Operating Procedure (SOP) outlines the process by which the Principal Investigator (PI) delegates the authority to conduct clinical study procedures and tasks to sub-investigators and other study personnel. It also details the maintenance of documentation related to staff and investigator signatures and handwriting samples. Scope: The PI conducting a clinical trial must adhere to regulations governing informed consent (21 CFR 50) and regulations regarding Institutional Review Board (IRB) review and approval (21 CFR 56). If the study involves an investigational drug or device, additional regulations in 21 CFR 312 or 21 CFR 812 apply. Furthermore, all clinical study investigators should follow the International Council on Harmonization (ICH) guidelines for Good Clinical Practice (GCP). While these responsibilities are primarily held by the PI, they can be delegated to qualified sub-investigators and other...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more